JP2021172648A - 多成分配合点眼剤 - Google Patents
多成分配合点眼剤 Download PDFInfo
- Publication number
- JP2021172648A JP2021172648A JP2020089215A JP2020089215A JP2021172648A JP 2021172648 A JP2021172648 A JP 2021172648A JP 2020089215 A JP2020089215 A JP 2020089215A JP 2020089215 A JP2020089215 A JP 2020089215A JP 2021172648 A JP2021172648 A JP 2021172648A
- Authority
- JP
- Japan
- Prior art keywords
- salt
- eye drop
- component
- hydrochloride
- chlorobutanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000004615 ingredient Substances 0.000 title abstract description 7
- 239000002997 ophthalmic solution Substances 0.000 title abstract 4
- 229940054534 ophthalmic solution Drugs 0.000 title abstract 4
- 239000003889 eye drop Substances 0.000 claims abstract description 93
- 150000003839 salts Chemical class 0.000 claims abstract description 35
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 35
- CNIIGCLFLJGOGP-UHFFFAOYSA-N 2-(1-naphthalenylmethyl)-4,5-dihydro-1H-imidazole Chemical compound C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 CNIIGCLFLJGOGP-UHFFFAOYSA-N 0.000 claims abstract description 25
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims abstract description 24
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 claims abstract description 24
- 239000011764 pyridoxine hydrochloride Substances 0.000 claims abstract description 24
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 claims abstract description 21
- 229940046978 chlorpheniramine maleate Drugs 0.000 claims abstract description 21
- 229960003080 taurine Drugs 0.000 claims abstract description 17
- 229920001287 Chondroitin sulfate Polymers 0.000 claims abstract description 15
- 229960004949 glycyrrhizic acid Drugs 0.000 claims abstract description 12
- 235000019410 glycyrrhizin Nutrition 0.000 claims abstract description 12
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 12
- 229940059329 chondroitin sulfate Drugs 0.000 claims abstract description 11
- 229960005016 naphazoline Drugs 0.000 claims abstract description 11
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims abstract description 7
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 claims description 68
- 229940012356 eye drops Drugs 0.000 claims description 47
- 229960004926 chlorobutanol Drugs 0.000 claims description 34
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 21
- 239000004327 boric acid Substances 0.000 claims description 20
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 claims description 18
- DJDFFEBSKJCGHC-UHFFFAOYSA-N Naphazoline Chemical compound Cl.C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 DJDFFEBSKJCGHC-UHFFFAOYSA-N 0.000 claims description 18
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 claims description 18
- 239000003755 preservative agent Substances 0.000 claims description 18
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 17
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 16
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 16
- 229940068968 polysorbate 80 Drugs 0.000 claims description 16
- 229920000053 polysorbate 80 Polymers 0.000 claims description 16
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 16
- -1 chondroitin sulfate ester Chemical class 0.000 claims description 14
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 12
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 12
- 230000002335 preservative effect Effects 0.000 claims description 11
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 claims description 8
- 229960004760 naphazoline hydrochloride Drugs 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 6
- 239000003381 stabilizer Substances 0.000 claims description 6
- FPXKNYVSOKOLKD-BTJKTKAUSA-N (z)-but-2-enedioic acid;n-chloroaniline Chemical compound OC(=O)\C=C/C(O)=O.ClNC1=CC=CC=C1 FPXKNYVSOKOLKD-BTJKTKAUSA-N 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 abstract description 28
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 abstract description 16
- 238000003860 storage Methods 0.000 abstract description 15
- 238000001556 precipitation Methods 0.000 abstract description 13
- 239000000654 additive Substances 0.000 abstract description 10
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 abstract description 8
- 229960000458 allantoin Drugs 0.000 abstract description 8
- 230000000996 additive effect Effects 0.000 abstract description 7
- 238000000354 decomposition reaction Methods 0.000 abstract description 7
- 238000002845 discoloration Methods 0.000 abstract description 6
- 239000000243 solution Substances 0.000 abstract description 6
- 229960004172 pyridoxine hydrochloride Drugs 0.000 abstract description 3
- 230000008021 deposition Effects 0.000 abstract 1
- 235000002639 sodium chloride Nutrition 0.000 description 24
- 230000000052 comparative effect Effects 0.000 description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 21
- 235000010338 boric acid Nutrition 0.000 description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 17
- 230000000694 effects Effects 0.000 description 14
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 13
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 13
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 13
- 229960002684 aminocaproic acid Drugs 0.000 description 13
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 13
- 239000008213 purified water Substances 0.000 description 12
- 229940037001 sodium edetate Drugs 0.000 description 12
- 229940006423 chondroitin sulfate sodium Drugs 0.000 description 11
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 11
- 235000019477 peppermint oil Nutrition 0.000 description 11
- 239000000047 product Substances 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 9
- 238000002156 mixing Methods 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 238000000034 method Methods 0.000 description 8
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 7
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 229910000397 disodium phosphate Inorganic materials 0.000 description 6
- 235000019800 disodium phosphate Nutrition 0.000 description 6
- OTNVGWMVOULBFZ-UHFFFAOYSA-N sodium;hydrochloride Chemical compound [Na].Cl OTNVGWMVOULBFZ-UHFFFAOYSA-N 0.000 description 6
- 229940045613 taurine 1000 mg Drugs 0.000 description 6
- 230000009471 action Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000003204 osmotic effect Effects 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 230000000172 allergic effect Effects 0.000 description 4
- 208000010668 atopic eczema Diseases 0.000 description 4
- 229940107200 chondroitin sulfates Drugs 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229920000136 polysorbate Polymers 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000013329 compounding Methods 0.000 description 3
- 206010015907 eye allergy Diseases 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 229950008882 polysorbate Drugs 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 2
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000002205 allergic conjunctivitis Diseases 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 208000003464 asthenopia Diseases 0.000 description 2
- 208000024998 atopic conjunctivitis Diseases 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 2
- 239000001685 glycyrrhizic acid Substances 0.000 description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- WYWIFABBXFUGLM-UHFFFAOYSA-N oxymetazoline Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 description 2
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000017550 sodium carbonate Nutrition 0.000 description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- DTGKSKDOIYIVQL-NQMVMOMDSA-N (+)-Borneol Natural products C1C[C@]2(C)[C@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-NQMVMOMDSA-N 0.000 description 1
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- WJLVQTJZDCGNJN-UHFFFAOYSA-N Chlorhexidine hydrochloride Chemical compound Cl.Cl.C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 WJLVQTJZDCGNJN-UHFFFAOYSA-N 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 208000016134 Conjunctival disease Diseases 0.000 description 1
- 208000028006 Corneal injury Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000005792 Geraniol Substances 0.000 description 1
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010023644 Lacrimation increased Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 235000014435 Mentha Nutrition 0.000 description 1
- 241001072983 Mentha Species 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- ILRKKHJEINIICQ-OOFFSTKBSA-N Monoammonium glycyrrhizinate Chemical compound N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ILRKKHJEINIICQ-OOFFSTKBSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- YYVFXSYQSOZCOQ-UHFFFAOYSA-N Oxyquinoline sulfate Chemical compound [O-]S([O-])(=O)=O.C1=C[NH+]=C2C(O)=CC=CC2=C1.C1=C[NH+]=C2C(O)=CC=CC2=C1 YYVFXSYQSOZCOQ-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000593989 Scardinius erythrophthalmus Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 239000004288 Sodium dehydroacetate Substances 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000003732 agents acting on the eye Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 229960002645 boric acid Drugs 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960004504 chlorhexidine hydrochloride Drugs 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 239000001926 citrus aurantium l. subsp. bergamia wright et arn. oil Substances 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- LVXHNCUCBXIIPE-UHFFFAOYSA-L disodium;hydrogen phosphate;hydrate Chemical compound O.[Na+].[Na+].OP([O-])([O-])=O LVXHNCUCBXIIPE-UHFFFAOYSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229940113087 geraniol Drugs 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000004317 lacrimation Effects 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000011147 magnesium chloride Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 1
- 229960004186 naphazoline nitrate Drugs 0.000 description 1
- 229940125702 ophthalmic agent Drugs 0.000 description 1
- 229960001528 oxymetazoline Drugs 0.000 description 1
- 229960001257 oxyquinoline sulfate Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 229920001987 poloxamine Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019259 sodium dehydroacetate Nutrition 0.000 description 1
- 229940079839 sodium dehydroacetate Drugs 0.000 description 1
- BBMHARZCALWXSL-UHFFFAOYSA-M sodium dihydrogenphosphate monohydrate Chemical compound O.[Na+].OP(O)([O-])=O BBMHARZCALWXSL-UHFFFAOYSA-M 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- DSOWAKKSGYUMTF-GZOLSCHFSA-M sodium;(1e)-1-(6-methyl-2,4-dioxopyran-3-ylidene)ethanolate Chemical compound [Na+].C\C([O-])=C1/C(=O)OC(C)=CC1=O DSOWAKKSGYUMTF-GZOLSCHFSA-M 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 230000003639 vasoconstrictive effect Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
【解決手段】有効成分として、ナファゾリン又はその塩、アラントイン、グリチルリチン酸又はその塩、クロルフェニラミンマレイン酸塩、ピリドキシン塩酸塩、タウリン及びコンドロイチン硫酸エステル又はその塩の7成分を含有する多成分配合点眼剤に於いて、特定の添加物を使用すること、並びに、添加物の含有量や点眼剤のpHを特定の範囲に調製することで上記課題を解決した。
【選択図】なし
Description
(1)有効成分として、ナファゾリン又はその塩、アラントイン、グリチルリチン酸又はその塩、クロルフェニラミンマレイン酸塩、ピリドキシン塩酸塩、タウリン及びコンドロイチン硫酸エステル又はその塩を含有する多成分配合点眼剤。
(2)ナファゾリン又はその塩がナファゾリン塩酸塩であり、グリチルリチン酸又はその塩がグリチルリチン酸二カリウムであり、コンドロイチン硫酸エステル又はその塩がコンドロイチン硫酸エステルナトリウムである、(1)に記載の多成分配合点眼剤。
(3)0.001w/v%のナファゾリン塩酸塩、0.3w/v%のアラントイン、0.25w/v%のグリチルリチン酸二カリウム、0.03w/v%のクロルフェニラミンマレイン酸塩、0.1w/v%のピリドキシン塩酸塩、1.0w/v%のタウリン及び0.5w/v%のコンドロイチン硫酸エステルナトリウムを含有する、(1)又は(2)に記載の多成分配合点眼剤。
(4)さらに安定化剤としてホウ酸を含有する、(1)から(3)のいずれか1つに記載の多成分配合点眼剤。
(5)ホウ酸を0.25から1.0w/v%含有する、(4)に記載の多成分配合点眼剤。
(6)さらに防腐剤を含有する、(1)から(5)のいずれか1つに記載の多成分配合点眼剤。
(7)前記防腐剤が、クロロブタノール、パラオキシ安息香酸エチル、パラオキシ安息香酸プロピル及びベンザルコニウム塩化物からなる群から選択される2成分以上である、(6)に記載の多成分配合点眼剤。
(8)前記防腐剤が、クロロブタノール、パラオキシ安息香酸エチル及びパラオキシ安息香酸プロピルの3成分からなる、(6)又は(7)に記載の多成分配合点眼剤。
(9)クロロブタノールを0.25w/v%、パラオキシ安息香酸エチルを0.013w/v%、パラオキシ安息香酸プロピルを0.007w/v%含有する、(8)に記載の多成分配合点眼剤。
(10)前記防腐剤がクロロブタノール及びベンザルコニウム塩化物の2成分からなる、(6)又は(7)に記載の多成分配合点眼剤。
(11)クロロブタノールを0.25w/v%、ベンザルコニウム塩化物を0.01%含有する、(10)に記載の多成分配合点眼剤。
(12)さらに溶解補助剤としてポリソルベート80を含有する、(10)又は(11)に記載の多成分配合点眼剤。
(13)ポリソルベート80を0.02w/v%以下含有する、(12)に記載の多成分配合点眼剤。
(14)pHが5.0から5.5の範囲にある、(1)から(13)のいずれか1つに記載の多成分配合点眼剤。
ナファゾリン塩酸塩1mg、アラントイン300mg、グリチルリチン酸二カリウム250mg、クロルフェニラミンマレイン酸塩30mg、ピリドキシン塩酸塩100mg、タウリン1000mg、コンドロイチン硫酸エステルナトリウム500mg、イプシロンアミノカプロン酸500mg、リン酸水素ナトリウム水和物600mg、エデト酸ナトリウム水和物10mg、ハッカ油3mg、l−メントール40mg、クロロブタノール250mg、パラオキシ安息香酸エチル13mg、パラオキシ安息香酸プロピル7mg及びプロピレングリコール500mgを精製水に溶解し、全量を100mLとして調製した。
ナファゾリン塩酸塩1mg、アラントイン300mg、グリチルリチン酸二カリウム250mg、クロルフェニラミンマレイン酸塩30mg、ピリドキシン塩酸塩100mg、タウリン1000mg、コンドロイチン硫酸エステルナトリウム500mg、イプシロンアミノカプロン酸500mg、ホウ酸60mg、リン酸水素ナトリウム水和物230mg、エデト酸ナトリウム水和物10mg、ハッカ油3mg、l−メントール40mg、クロロブタノール250mg、パラオキシ安息香酸エチル13mg、パラオキシ安息香酸プロピル7mg及びプロピレングリコール500mgを精製水に溶解し、全量を100mLとして調製した。
ナファゾリン塩酸塩1mg、アラントイン300mg、グリチルリチン酸二カリウム250mg、クロルフェニラミンマレイン酸塩30mg、ピリドキシン塩酸塩100mg、タウリン1000mg、コンドロイチン硫酸エステルナトリウム500mg、イプシロンアミノカプロン酸500mg、ホウ酸690mg、リン酸水素ナトリウム水和物50mg、エデト酸ナトリウム水和物10mg、ハッカ油3mg、l−メントール40mg、クロロブタノール250mg、ベンザルコニウム塩化物10mg及びポリソルベート80 80mgを精製水に溶解し、全量を100mLとして調製した。
ナファゾリン塩酸塩10mg、アラントイン3000mg、グリチルリチン酸二カリウム2500mg、クロルフェニラミンマレイン酸塩300mg、ピリドキシン塩酸塩1000mg、タウリン10000mg、コンドロイチン硫酸エステルナトリウム5000mg、イプシロンアミノカプロン酸2000mg、ホウ酸7000mg、リン酸水素ナトリウム水和物6200mg、エデト酸ナトリウム水和物100mg、ハッカ油30mg、l−メントール400mg、クロロブタノール2500mg、パラオキシ安息香酸エチル130mg、パラオキシ安息香酸プロピル70mg及びプロピレングリコール5000mgを精製水に溶解し、全量を1000mLとして調製した。
ナファゾリン塩酸塩10mg、アラントイン3000mg、グリチルリチン酸二カリウム2500mg、クロルフェニラミンマレイン酸塩300mg、ピリドキシン塩酸塩1000mg、タウリン10000mg、コンドロイチン硫酸エステルナトリウム5000mg、イプシロンアミノカプロン酸2000mg、ホウ酸7000mg、リン酸水素ナトリウム水和物3000mg、エデト酸ナトリウム水和物100mg、ハッカ油30mg、l−メントール400mg、クロロブタノール2500mg、ベンザルコニウム塩化物100mg及びポリソルベート80 200mgを精製水に溶解し、全量を1000mLとして調製した。
ナファゾリン塩酸塩10mg、アラントイン3000mg、グリチルリチン酸二カリウム2500mg、クロルフェニラミンマレイン酸塩300mg、ピリドキシン塩酸塩1000mg、タウリン10000mg、コンドロイチン硫酸エステルナトリウム5000mg、イプシロンアミノカプロン酸2000mg、ホウ酸7000mg、リン酸水素ナトリウム水和物6200mg、エデト酸ナトリウム水和物100mg、ハッカ油30mg、l−メントール400mg、クロロブタノール2500mg、ベンザルコニウム塩化物100mg及びポリソルベート80 200mgを精製水に溶解し、全量を1000mLとして調製した。
7種類の有効成分を含有する多成分配合点眼剤について、安定化剤であるホウ酸の添加量、pH及び浸透圧を変えて調製した実施例1、実施例2、実施例5、比較例1、比較例2及び比較例4の多成分配合点眼剤を各々50℃で2箇月間保存し、薬液の性状変化を各々評価した、その結果を以下に示す。
7種類の有効成分を含有する多成分配合点眼剤について、防腐剤としてクロロブタノールを0.25w/v%及びベンザルコニウム塩化物を0.01w/v%添加し、さらに、溶解補助剤であるポリソルベート80を添加しなかった実施例3、ポリソルベ−ト80を0.02w/v%添加した実施例4、ポリソルベ−ト80を0.08w/v%添加した比較例3の多成分配合点眼剤を50℃で2箇月間保存し、薬液の性状変化を評価した、その結果を以下に示す。
7種類の有効成分を含有する多成分配合点眼剤について、防腐剤としてクロロブタノール、並びに、パラオキシ安息香酸エチル及びパラオキシ安息香酸プロピル又はベンザルコニウム塩化物を用いて調製した実施例4、実施例5、比較例4、比較例5及び比較例6の多成分配合点眼剤を各々40℃及び50℃で保存し、pH、浸透圧及び有効成分の含量の変化を各々評価した。その結果を以下に示す。
実施例6及び実施例7の多成分配合点眼剤について、第十七改正日本薬局方の保存効力試験法に基づいて試験を実施した。
Claims (14)
- 有効成分として、ナファゾリン又はその塩、アラントイン、グリチルリチン酸又はその塩、クロルフェニラミンマレイン酸塩、ピリドキシン塩酸塩、タウリン及びコンドロイチン硫酸エステル又はその塩を含有する多成分配合点眼剤。
- ナファゾリン又はその塩がナファゾリン塩酸塩であり、グリチルリチン酸又はその塩がグリチルリチン酸二カリウムであり、コンドロイチン硫酸エステル又はその塩がコンドロイチン硫酸エステルナトリウムである、請求項1に記載の多成分配合点眼剤。
- 0.001w/v%のナファゾリン塩酸塩、0.3w/v%のアラントイン、0.25w/v%のグリチルリチン酸二カリウム、0.03w/v%のクロルフェニラミンマレイン酸塩、0.1w/v%のピリドキシン塩酸塩、1.0w/v%のタウリン及び0.5w/v%のコンドロイチン硫酸エステルナトリウムを含有する、請求項1又は2に記載の多成分配合点眼剤。
- さらに安定化剤としてホウ酸を含有する、請求項1から3のいずれか1項に記載の多成分配合点眼剤。
- ホウ酸を0.25から1.0w/v%含有する、請求項4に記載の多成分配合点眼剤。
- さらに防腐剤を含有する、請求項1から5のいずれか1項に記載の多成分配合点眼剤。
- 前記防腐剤が、クロロブタノール、パラオキシ安息香酸エチル、パラオキシ安息香酸プロピル及びベンザルコニウム塩化物からなる群から選択される2成分以上である、請求項6に記載の多成分配合点眼剤。
- 前記防腐剤が、クロロブタノール、パラオキシ安息香酸エチル及びパラオキシ安息香酸プロピルの3成分からなる、請求項6又は7に記載の多成分配合点眼剤。
- クロロブタノールを0.25w/v%、パラオキシ安息香酸エチルを0.013w/v%、パラオキシ安息香酸プロピルを0.007w/v%含有する、請求項8に記載の多成分配合点眼剤。
- 前記防腐剤がクロロブタノール及びベンザルコニウム塩化物の2成分からなる、請求項6又は7に記載の多成分配合点眼剤。
- クロロブタノールを0.25w/v%、ベンザルコニウム塩化物を0.01%含有する、請求項10に記載の多成分配合点眼剤。
- さらに溶解補助剤としてポリソルベート80を含有する、請求項10又は11に記載の多成分配合点眼剤。
- ポリソルベート80を0.02w/v%以下含有する、請求項12に記載の多成分配合点眼剤。
- pHが5.0から5.5の範囲にある、請求項1から13のいずれか1項に記載の多成分配合点眼剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020089215A JP7534129B2 (ja) | 2020-04-18 | 2020-04-18 | 多成分配合点眼剤 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020089215A JP7534129B2 (ja) | 2020-04-18 | 2020-04-18 | 多成分配合点眼剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021172648A true JP2021172648A (ja) | 2021-11-01 |
JP7534129B2 JP7534129B2 (ja) | 2024-08-14 |
Family
ID=78279597
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020089215A Active JP7534129B2 (ja) | 2020-04-18 | 2020-04-18 | 多成分配合点眼剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP7534129B2 (ja) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012144509A (ja) | 2011-01-12 | 2012-08-02 | Saga Seiyaku Kk | 多成分配合の点眼剤 |
-
2020
- 2020-04-18 JP JP2020089215A patent/JP7534129B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP7534129B2 (ja) | 2024-08-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5244584B2 (ja) | キサンタンガムおよびブドウ糖を含有する眼科用組成物 | |
JP6603785B2 (ja) | 水溶性高分子を含む水性液剤 | |
KR101322527B1 (ko) | 잔탄 검 및 테르페노이드를 포함하는 점안제 | |
US10220043B2 (en) | Aqueous composition | |
JP2022504746A (ja) | 老視の治療のための組成物及び方法 | |
WO2019189721A1 (ja) | 水性液剤 | |
CN106455567A (zh) | 用于治疗青光眼的组合物和方法 | |
JP2019006776A (ja) | 水溶性高分子を含む点眼剤 | |
JP2023181428A (ja) | 眼科用組成物 | |
JP2015067607A (ja) | 複数の成分を配合した点眼剤 | |
KR102633606B1 (ko) | 활성 성분으로서 티오트로피움을 포함하는, 근시 예방, 근시 치료, 및/또는 근시 진행 예방을 위한 제제 | |
JP2021172648A (ja) | 多成分配合点眼剤 | |
JP6213715B2 (ja) | 多成分配合点眼剤 | |
JP2005247802A (ja) | 点眼剤 | |
JP5838718B2 (ja) | ソフトコンタクトレンズ用眼科組成物及び吸着抑制方法 | |
WO2013047373A1 (ja) | 亜塩素酸塩を含有する水性製剤 | |
JP5560588B2 (ja) | 眼科用剤 | |
US20230414587A1 (en) | Compositions and methods for storage stable ophthalmic drugs | |
KR102444571B1 (ko) | 세티리진 및 토코페솔란을 포함하는 안과용 조성물 | |
JP4470393B2 (ja) | 安定である点眼剤 | |
JP5460996B2 (ja) | 眼科用剤 | |
JP2016113458A (ja) | 新水性組成物 | |
JP6571391B2 (ja) | 水性製剤 | |
WO2021245610A2 (en) | Novel pharmaceutical composition comprising combination of olopatadine and nepafenac | |
KR20230131822A (ko) | 저장 안정성 안약을 위한 조성물 및 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230414 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240123 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240318 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240723 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240801 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7534129 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |